samedan logo
 
 
 
spacer
home > ebr > autumn 2019 > the next-generation purification of monoclonal antibodies
PUBLICATIONS
European Biopharmaceutical Review

The Next-Generation Purification of Monoclonal Antibodies




There is unprecedented pressure on the biopharmaceutical industry to improve the performance of monoclonal antibody (mAb) development and manufacturing processes. There are several factors essential to addressing this challenge, including flexibility (in which product changeover time is reduced), quality (as defined by increased robustness and reliability), speed (in which production and product release are accelerated), and cost reductions in manufacturing and capital expenditure.

Improvements in processes and productivity can enable smaller and simpler facilities and lower costs, leading to several advantages, including the ability to:

• Improve competitiveness and long-term sustainability
• Enable business models for new biologics and novel therapies
• Supply developing countries with affordable biologics
• Reach emerging markets profitably

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Skarja is the Head of Membrane Chromatography R&D at Merck. He has 20 years of experience leading dynamic R&D teams in a variety of life sciences sectors, including biopharma, medical device, and cell and gene therapy. Gary holds over 20 patents related to novel polymers, devices, and processes for life sciences applications. He has Bachelor’s and Master’s Degrees in Chemical Engineering from McMaster University, Canada, and a PhD in Chemical Engineering from the University of Toronto, Canada.
spacer
Gary Skarja
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera wins Pharmapack Award in Connected Devices and Wearables category with its body injector platform Symbioze

Symbioze, the smart, high volume and sustainable on-body injector platform developed by Nemera, wins the ‘Connected Devices and Wearables’ Award at Pharmapack 2021 On October 12th, during the Pharmapack Awards Ceremony, a team of industry experts awarded Symbioze, Nemera’s large-volume on-body injector, with the Pharmapack Award in the “Connected Devices and Wearables” category.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement